Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 9Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Anemia 1

Interventions

Carboplatin 158Pemetrexed 135Cisplatin 115pembrolizumab 99Docetaxel 94Paclitaxel 89Gemcitabine 63Erlotinib Hydrochloride 61Radiotherapy 55Nivolumab 55Bevacizumab 46Etoposide 42atezolizumab 34Radiosurgery 33durvalumab 28Cyclophosphamide 22Vinorelbine 21Ipilimumab 21Radiation 20Taxes 17130-nm albumin-bound paclitaxel 17Albumin-Bound Paclitaxel 16Gefitinib 14Irinotecan 13Drug Therapy 13osimertinib 12avelumab 12Magnetic Resonance Spectroscopy 12Dexamethasone 12Cetuximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Epoetin Alfa × Thoracic × Clear all
NCT00310232 2024-04-02

Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

Ontario Clinical Oncology Group (OCOG)

Phase 3 Terminated
70 enrolled
Classical hematologyThoracic

Anemia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡